FORM 4

UNITED STATES SE

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

CURITIES AND	EXCHANGE	COMMISSION

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average burden									

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended
to satisfy the affirmative defense conditions of Rule 10b5-1(c). See

Instructio	n 10.																			
Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol C4 Therapeutics, Inc. [CCCC]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Hirsch Andrew					C4 Therapeuties, me. [CCCC]								Directo	r		10% Ov	vner			
(Loot) (First) (Middle)						2. Data of English Transportion (Month/Day/Year)								Officer (give title Other (specification) below)			specify			
(Last) (First) (Middle) C/O C4 THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 09/16/2024								President & CEO						
490 ARSENAL WAY #120																				
(Street)					4. lf <i>i</i>	Amen	ndment	, Date of	f Original	Filed	(Month/Day	y/Year)		6. Individual or Joint/Group Filing (Check Applicable Line)						
, ,	OWN MA	0:	2472											Form filed by One Reporting Person						
														Form filed by More than One Reporting Person						
(City)	(Sta	te) (Z	ľip)																	
		Table	e I - Nor	ı-Deriv	ative	Sec	curitie	es Acc	quired,	Dis	posed o	f, or Be	neficiall	y Owned						
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ır) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amour Securitie Beneficia Owned F Reported	es Fo ially (D Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(Instr. 4)			
Common Stock			09/10	5/2024				М		7,500	A	(1)	218,241			D				
Common Stock (09/10	6/2024				F ⁽²⁾		3,329 D		\$6.36	214,912			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) 3. Machine Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number 6		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)						
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares							
Performance Restricted Stock Units	(1)	09/16/2024			M			7,500	(1)		02/28/2025	Common Stock	7,500	\$0	47,500	0	D			

Explanation of Responses:

- 1. Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
- 2. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.

Remarks:

/s/ Jolie M. Siegel, Attorney-in-09/17/2024

Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.